At the latest JP Morgan Healthcare Conference in 2025, NVIDIA and Innophore announced an exciting collaboration to launch an AI-driven drug safety screening platform named CavitOmiX by the end of January 2025. This platform aims to improve the efficiency and accuracy of drug design through the analysis of protein binding sites, marking a revolutionary transformation in the field of drug development. Christian Gruber, CEO of Innophore.